

CLAIMS

1. A method of treating a bacterial infection in a mammal comprising administering to a mammal in need of such treatment effective amounts of  
5 azithromycin and a glycogen phosphorylase inhibitor.
2. The method of claim 1 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.  
10
3. The method of claim 1 wherein said bacterial infection is a *Chlamydia pneumoniae* infection.
4. A method of treating a *Chlamydia pneumoniae* infection comprising administering to a mammal comprising administering to a mammal in need of such  
15 treatment effective amounts of azithromycin and a glycogen phosphorylase inhibitor.
5. The method of claim 4 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.  
20
6. A method of treating atherosclerosis comprising administering to a mammal in need of such treatment effective amounts of azithromycin and a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt thereof or prodrug thereof.
- 25 7. The method of claim 6 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-fluorobenzyl)-2-(hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.
- 30 8. A pharmaceutical composition comprising, in effective amounts, azithromycin and a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt thereof and further comprising a pharmaceutical carrier or diluent.
9. A pharmaceutical composition of claim 8 wherein said glycogen phosphorylase is selected from the group consisting of 5-chloro-1H-indole-2-

carboxylic acid [(1S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.

10. A kit comprising:

- 5                   a)     azithromycin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b)     a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and
- 10                  c)     a container.

11. The kit of claim 10 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.

15

12. A kit comprising:

- a)     azithromycin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a unit dosage form; and
- 20                  b)     instructions for administering a glycogen phosphorylase to a mammal.

13. The kit of claim 12 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.

25

14. A kit comprising:

- a)     a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a unit dosage form; and
- 30                  b)     instructions for administering azithromycin to a mammal.

15. The kit of claim 14 wherein said glycogen phosphorylase inhibitor is selected from the group consisting of 5-chloro-1H-indole-2-carboxylic acid [(1S)-(4-

fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide and 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.